Downloads: 133 | Views: 215

Comparative Studies | Medicine Science | India | Volume 7 Issue 3, March 2018

Comparison of Ropivacaine 0.75% and Bupivacaine 0.5% in Peribulbar Block for Small Incision Cataract Surgery - A Prospective Randomized Controlled Study

Dr Shantala Arun Kumar | Dr Paresh Nagwekar | Dr Ashutosh Patel

Abstract: COMPARISON OF ROPIVACAINE 0.75 % AND BUPIVACAINE 0.5 % IN PERIBULBAR BLOCK FOR SMALL INCISION CATARACT SURGERY-A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. Dr Shanthala Arun Kumar, Professor and HOD, Department of Ophthalmology, SSIMS & RC, Davangere, Dr Paresh Nagwekar, Post graduate student, Department of Anaesthesiology, Pain and Critical care, SSIMS & RC, Davangere, Dr Ashutosh Patel, Department of Ophthalmology, SSIMS & RC, Davangere. BACKGROUND Ropivacaine is amide local anaesthetic agent. The aims of study are to assess the anaesthetic efficacy of 0.75 % ropivacaine as a peribulbar block in cataract surgery and to compare the anaesthetic efficacy of 0.75 % ropivacaine vs 0.5 % bupivacaine. MATERIALS AND METHODS After ethical committee clearance and taking written informed consent from patients they will be randomized to receive peribulbar anaesthesia using 0.75 % ropivacaine with hyaluronidase 50 IU/ml in group R (n=25) and 0.5 % bupivacaine with hyaluronidase 50 IU/ml in group B (n=25). Inclusion criteria is ASA I & II patients. Exclusion criteria is patients refusing consent, taking anticoagulants etc. . Parameters studied are akinesia score, visual analogue score and first dose of rescue analgesia needed post-operatively after peribulbar block. The power of study was kept at 80 %. Chi square test and Fischer test are statistical tests used. RESULTS GROUP N Mean Std. Deviation t value p value AKINESIA GROUP B 25 2.48.714 10.362 0.000 GROUP R 25 1.00 0.000 CONCLUSION Ropivacaine may be a more appropriate anesthetic for peribulbar anesthesia than bupivacaine. S Bupivacaine, Ropivacaine, Peribulbar block

Keywords: Bupivacaine, Ropivacaine, Peribulbar block

Edition: Volume 7 Issue 3, March 2018,

Pages: 1129 - 1130